Arbutus Biopharma ABUS
NASDAQ ABUS
$5.15 +0.03 (+0.59%)
As of: Sep 4, 2026 · 3:59 PM EDT

Arbutus Biopharma (ABUS) EV to CFO (2013 - 2026)

Analysis

Arbutus Biopharma (ABUS) EV to CFO (2013 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Arbutus Biopharma 1.02 Bn 927.31 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -142.24
Mar 31, 2026 -97.54
Dec 31, 2025 -178.33
Sep 30, 2025 -133.71
Jun 30, 2025 -31.37
Mar 31, 2025 -41.49
Dec 31, 2024 -48.33
Sep 30, 2024 -29.01
Jun 30, 2024 -30.42
Mar 31, 2024 -17.40
Dec 31, 2023 -17.27
Sep 30, 2023 -9.47
Jun 30, 2023 -11.83
Mar 31, 2023 -12.95
Dec 31, 2022 -12.95
Sep 30, 2022 -8.40
Jun 30, 2022 -12.47
Mar 31, 2022 13.47
Dec 31, 2021 -13.16
Sep 30, 2021 -21.93